Register Now for NAAF's 39th Annual Patient Conference June 27-30, 2024 in Washington, D.C.!

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult Participants With Severe Alopecia Areata (Up-AA)

Study type: Clinical Trials Posting date: 05/21/2024 Last updated: 05/21/2024 Status: Recruiting Phase: Phase 3 Country: United States Eligibility:

Age 18 to < 64; diagnosis of severe AA; 50% or greater scalp hair loss; experienceing current episode of AA for less than 8 years

Drug: upadacitinib Administration: Oral Sponsor: AbbVie Sponsor Link: Click here link: Click here Location: Multiple locations


For more information go to: